Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rh-associated glycoprotein (RHAG) is an ammonia transporter protein encoded by the RHAG gene and primarily expressed in human erythrocytes[1][3]. It is a component of the multisubunit Rh antigen complex, which includes RHAG, Rh30 (D/CE) polypeptides, CD47, LW, and glycophorin B[1][4]. RHAG facilitates the movement of ammonia (NH₃) and methylamine across the red blood cell membrane and may also act as a gas channel for CO₂ and possibly O₂ and nitric oxide[2][3]. It is structurally homologous to ammonium transporter families found in bacteria and yeast. RHAG is essential for proper presentation of the Rh blood group antigens on the cell surface; mutations can result in hereditary stomatocytosis and other blood cell membrane disorders[1][4]. It is referenced as CD241 in immunophenotyping applications and is a member of the solute carrier family under the gene name SLC42A1[1]. No approved drugs are known to directly target RHAG, but its dysfunction has clinical implications in hematology and transfusion medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rh-associated glycoprotein (RHAG).